CLYYF — Stock Film
STOCK FILMSCENE 1/11CLYYF · $0.20
Stock Expert AI presents
CLYYF
Celyad Oncology S.A
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Celyad Oncology S.A. A quick introduction.

On the stock market since 2014, it operates in the world of health and science. It has 17 employees. Now — the numbers.

on the stock market since 2014
17 employees
$9M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $3953 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 3953%

This is an established company with proven profits.

THE SALES TREND
The sales picture, year by year.

Red columns mark years that ended in a loss.

$0
2021
$0
2022
$102K
2023
$186K
2024
$21K
2025
Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $1.7M would still be left in the vault — a solid cushion for hard times.

Every quarter, analysts set a profit bar.
How many of the last 5 did the company clear?
4 / 5
EXPECTATIONS MET OR BEATEN
4
Dec 2021
Jun 2022
Mar 2023
Jun 2023
Apr 2024
4 TIMES IN THE LAST 5 QUARTERS
It clears the bar, quarter after quarter.
THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
Heavy investment in the future10/10
WEAK SPOTS
Growth has stalled2/10
Heavy bets against the stock2/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
A fat but narrowing margin

The net profit margin is 3,953% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/2
Strong cash, light debt

There is $1.7M in the vault; even if every debt were paid off, $1.7M would remain.

1
THE RISKS · 1/3
Trading under $1

The stock sits at $0.20. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

2
THE RISKS · 2/3
Growth has stalled

The sales tempo runs behind the sector. Council score: 2/10.

3
THE RISKS · 3/3
Heavy bets against the stock

The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, CLYYF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: CLYYF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 24, 2026 · stockexpertai.com · Stock Film